


Oncology Pipeline



Phase I

<ul style="list-style-type: none"> Anti-GPRC5D (RG6234) Hematology 	<ul style="list-style-type: none"> Codrituzumab (glypican-3 MAb) (CHU)^a Gastrointestinal 	<ul style="list-style-type: none"> Ipatasertib (AKT inhibitor) (RG7440)^a Genitourinary 	<ul style="list-style-type: none"> Cibisatamab (CEA x CD3) (RG7802) Solid Tumors
<ul style="list-style-type: none"> Atezolizumab (anti-PD-L1 MAb) (RG7446) Lung (ES-SCLC), Solid Tumor 	<ul style="list-style-type: none"> FAP x 4-1BBL (RG7827) Solid Tumor 	<ul style="list-style-type: none"> KRAS G12C (RG6330) Solid Tumor 	<ul style="list-style-type: none"> Runimotamab (HER2 x CD3) (RG6194) Breast
<ul style="list-style-type: none"> Autogene cevumeran (iNeST) (RG6180)^a Solid Tumor 	<ul style="list-style-type: none"> FAP x CD40 (RG6189) Solid Tumor 	<ul style="list-style-type: none"> MAGE-A4 ImmTAC (RG6290)^a Solid Tumor 	<ul style="list-style-type: none"> SHP2i (SHP2 inhibitor) (RG6433) Solid Tumor
<ul style="list-style-type: none"> Belvarafenib (pan-RAF inhibitor) (RG6185) Solid Tumor 	<ul style="list-style-type: none"> Giredestrant (SERD) (RG6171) Breast 	<ul style="list-style-type: none"> Mosunetuzumab (CD20 x CD3) (RG7828) Hematology 	<ul style="list-style-type: none"> TGFβ (SOF10) (RG6440) Solid Tumor
<ul style="list-style-type: none"> CD137 agonist switch antibody (CHU)^b Solid Tumor 	<ul style="list-style-type: none"> Glofitamab (CD20 x CD3) (RG6026) Hematology 	<ul style="list-style-type: none"> NME (RG6286) Gastrointestinal 	<ul style="list-style-type: none"> Tiragolumab (anti-TIGIT MAb) (MTIG7192A, RG6058) Hematology, Solid Tumor
<ul style="list-style-type: none"> CD19 x 4-1BBL (RG6076) Hematology 	<ul style="list-style-type: none"> Glypican-3 x CD3 (CHU)^b Solid Tumor 	<ul style="list-style-type: none"> PBMC vaccine (SQZ)^c Solid Tumor 	<ul style="list-style-type: none"> TLR7 agonist (4) (RG6115) Gastrointestinal
<ul style="list-style-type: none"> CD25 MAb (RG6292) Solid Tumor 	<ul style="list-style-type: none"> HLA-A2-WT1 x CD3 (RG6007) Hematology (AML) 	<ul style="list-style-type: none"> PD-1 x IL2v (RG6279) Solid Tumor 	<ul style="list-style-type: none"> TYRP1 x CD3 (RG6232) Melanoma
<ul style="list-style-type: none"> Cevostamab (FcRH5 x CD3) (RG6160) Hematology 	<ul style="list-style-type: none"> IL15/IL15Ra-Fc (RG6323)^a Solid Tumor 	<ul style="list-style-type: none"> Venetoclax (BCL-2 inhibitor) (ABT-199, RG7601)^b Hematology (AML, MDS), Lung (SCLC) 	

Phase II

<ul style="list-style-type: none"> Atezolizumab (anti-PD-L1 MAb) (RG7446) Gynecologic (CC), Head and Neck (HNSCC), Lung (NSCLC) 	<ul style="list-style-type: none"> Glofitamab (CD20 x CD3) (RG6026) Hematology 	<ul style="list-style-type: none"> PD-1 x LAG3 (RG6139) Gastrointestinal 	<ul style="list-style-type: none"> Venetoclax (BCL-2 inhibitor) (ABT-199, RG7601)^b Hematology (MM)
<ul style="list-style-type: none"> Autogene cevumeran (iNeST) (RG6180)^a Melanoma 	<ul style="list-style-type: none"> Mosunetuzumab (CD20 x CD3) (RG7828) Hematology 	<ul style="list-style-type: none"> PD-1 x TIM3 (RG7769) Gastrointestinal 	<ul style="list-style-type: none"> rhPTX-2 (PRM-151, RG6354) Hematology (myelofibrosis)
<ul style="list-style-type: none"> Giredestrant (SERD) (RG6171) Breast 	<ul style="list-style-type: none"> Oncolytic type 5 adenovirus (CHU)^b Gastrointestinal 	<ul style="list-style-type: none"> Tiragolumab (anti-TIGIT MAb) (MTIG7192A, RG6058) Gynecologic, Head and Neck, Lung Gastrointestinal 	

Phase III

<ul style="list-style-type: none"> Atezolizumab (anti-PD-L1 MAb) (RG7446)^c Gastrointestinal, Genitourinary, Head and Neck (HNSCC), Lung, Breast 	<ul style="list-style-type: none"> Inavolisib (PI3K alpha inhibitor) (RG6114) Breast 	<ul style="list-style-type: none"> Tiragolumab (anti-TIGIT MAb) (MTIG7192A, RG6058) Gastrointestinal, Lung 	<ul style="list-style-type: none"> Trastuzumab Emtansine (T-DM1) (RG3502) Breast
<ul style="list-style-type: none"> Giredestrant (SERD) (RG6171) Breast 	<ul style="list-style-type: none"> Ipatasertib (AKT inhibitor) (RG7440)^a Genitourinary 	<ul style="list-style-type: none"> Venetoclax (BCL-2 inhibitor) (ABT-199, RG7601)^b Hematology (MM, MDS) 	<ul style="list-style-type: none"> Alectinib (ALK inhibitor) (RG7853) Lung (NSCLC)
<ul style="list-style-type: none"> Glofitamab (CD20 x CD3) (RG6026) Hematology (DLBCL) 	<ul style="list-style-type: none"> Mosunetuzumab (CD20 x CD3) (RG7828) Hematology (FL) 	<ul style="list-style-type: none"> Polatuzumab Vedotin (RG7596)^d Hematology (DLBCL) 	<ul style="list-style-type: none"> Entrectinib (RG6268) Lung (NSCLC)

These compounds and their uses are investigational and have not been approved by the US Food and Drug Administration or the European Medicines Agency. Efficacy and safety have not been established. The information presented should not be construed as a recommendation for use. The relevance of findings in preclinical studies to humans is currently being evaluated.

The Oncology Pipeline information is consistent with Roche's Q3 Year Results 2021 presentation (as of October 22, 2021). Available at <https://www.roche.com/dam/jcr:d7745cfb-1133-447e-9a5b-88b849495574/en/irp211020-a.pdf> and https://clinicaltrials.gov/ct2/results?term=Mosunetuzumab&age_v=&gndr=&type=&rsit=&phase=1&Search=Apply, https://clinicaltrials.gov/ct2/results?term=Glofitamab&age_v=&gndr=&type=&rsit=&phase=1&Search=Apply, <https://clinicaltrials.gov/ct2/results?cond=&term=RG6139&cntry=&state=&city=&dist=&v=&gndr=&type=&rsit=&phase=1&Search=Apply>, and, https://clinicaltrials.gov/ct2/results?term=tiragolumab&age_v=&gndr=&type=&rsit=&phase=1&Search=Apply

^aDeveloped in collaboration with BioNTech.

^bDeveloped in collaboration with Chugai.

^cDeveloped in collaboration with Xencor.

^dDeveloped in collaboration with Array BioPharma.

^eDeveloped in collaboration with Immunocore.

^fDeveloped in collaboration with SQZ Biotechnology.

^gDeveloped in collaboration with Blueprint Medicines.

^hJoint project with AbbVie.

ⁱDeveloped in collaboration with Exelixis.

^jDeveloped in collaboration with SeaGen

4-1BBL=4-1BB ligand; AKT=protein kinase B; BCL-2=B-cell lymphoma 2; CC=cervical cancer; CD=cluster of differentiation; CHU=Chugai; CLL=chronic lymphocytic leukemia; CRC=colorectal cancer; EC=esophageal cancer; FAP=fibroblast activation protein; FcRH5=Fc receptor homolog 5; G/GEJ=gastric and gastroesophageal junction; GPRC5D=G protein-coupled receptor class C group 5 member D; HER2=human epidermal growth factor receptor 2; HLA-A2-WT1=human leukocyte antigen-A2 Wilms' tumor protein 1; HNSCC=head and neck squamous cell carcinoma; Ig=immunoglobulin; IL2v=interleukin-2 variant; IL15=interleukin-15; IL15Ra-Fc=interleukin-15 receptor alpha Fc fusion protein; ImmTAC=immune mobilizing monoclonal TCRs against cancer; iNeST=Individualized Neoantigen-Specific Immunotherapy; ITIM=immunoreceptor tyrosine-based inhibition motif; KRAS G12C=Kirsten rat sarcoma viral oncogene homolog G12C mutation; LAG3=lymphocyte-activation gene 3; MAb=monoclonal antibody; MAGE-A4=melanoma-associated antigen A4; mCRPC=metastatic castration-resistant prostate cancer; MM=multiple myeloma; NHL=non-Hodgkin's lymphoma; NME=new molecular entity; NSCLC=non-small cell lung cancer; PDAC=pancreatic ductal adenocarcinoma; PBMC=peripheral blood mononuclear cell; PD-1=programmed cell death protein 1; PD-L1=programmed death-ligand 1; PI3K=phosphoinositide 3-kinase; RAF=rapidly accelerated fibrosarcoma; RCC=renal cell carcinoma; RET=rearranged during transfection; SCLC=small cell lung cancer; SERD=selective estrogen receptor degrader; SHP2i=Src homology-2 domain-containing protein tyrosine phosphatase-2 inhibitor; TCR=T-cell receptor; TGFβ=transforming growth factor beta; TIGIT=T-cell immunoreceptor with Ig and ITIM domains; TIM3=T-cell immunoglobulin mucin-3; TLR7=toll-like receptor 7; TYRP1=tyrosinase-related protein 1.